Galectin Therapeutics Files 8-K

Ticker: GALT · Form: 8-K · Filed: Feb 18, 2025 · CIK: 1133416

Galectin Therapeutics INC 8-K Filing Summary
FieldDetail
CompanyGalectin Therapeutics INC (GALT)
Form Type8-K
Filed DateFeb 18, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: 8-K, financials, corporate-filing

Related Tickers: GALT

TL;DR

GALECTIN THERAPEUTICS (GALT) filed an 8-K on Feb 18, 2025, reporting other events and financials.

AI Summary

Galectin Therapeutics Inc. filed an 8-K on February 18, 2025, reporting other events and financial statements. The company, formerly known as PRO PHARMACEUTICALS INC, is incorporated in Nevada and headquartered in Norcross, GA.

Why It Matters

This filing indicates routine corporate reporting, including financial statements and other events, which is important for investors to stay updated on the company's status.

Risk Assessment

Risk Level: low — This is a standard 8-K filing for reporting events and financial statements, not indicating any specific new risks.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

This 8-K filing is primarily to report 'Other Events' and 'Financial Statements and Exhibits' as of February 18, 2025.

When was Galectin Therapeutics Inc. incorporated?

Galectin Therapeutics Inc. was incorporated in Nevada.

What was the former name of Galectin Therapeutics Inc.?

The former name of Galectin Therapeutics Inc. was PRO PHARMACEUTICALS INC, with a date of name change on June 12, 2001.

Where is Galectin Therapeutics Inc. headquartered?

The company's principal executive office is located at 4960 PEACHTREE INDUSTRIAL BOULEVARD, STE 240, NORCROSS, GA 30071.

What is the SIC code for Galectin Therapeutics Inc.?

The Standard Industrial Classification (SIC) code for Galectin Therapeutics Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on February 18, 2025 regarding GALECTIN THERAPEUTICS INC (GALT).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing